Amgen Wins Next Step in Patent Dance Over PCSK9 Drugs

 

A Delaware jury found in Amgen’s favor after the company filed a patent infringement lawsuit against Sanofi and Regeneron Pharmaceuticals Inc. over its monoclonal antibodies that target proprotein convertase subtilisin/kexin type 9 (PCSK9), which are used in Amgen’s Repatha (evolocumab).

 

Amgen announced it will continue proceedings against Sanofi and Regeneron to collect damages and will seek an injunction to prevent the sale of their competitor PCSK9,